Core Viewpoint - 科济药业-B (02171) has seen a nearly 4% increase in stock price, currently trading at 16.27 HKD, with a transaction volume of 4.9417 million HKD. The company announced a clinical collaboration with Dispatch Bio to initiate a Phase I clinical trial in China by 2026, focusing on the application of the combined therapy DISP-11 in solid tumor patients [1]. Group 1 - The collaboration with Dispatch Bio involves the use of the Flare platform to develop a universal treatment for solid tumors [1]. - The combined therapy consists of Dispatch's investigational therapy, including the novel tumor-specific virus DV-10, and 科济药业's targeted BCMA autologous CAR-T cell product,赛恺泽 (泽沃基奥仑赛注射液) [1]. - 赛恺泽 has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1].
科济药业-B涨近4% 近日宣布与Dispatch Bio达成合作 计划开展赛恺泽相关临床试验